Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shexiang Baoxin Pill for angina due to non-obstructive coronary artery disease
ChiCTR2100044737Phase 4Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Mar 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Shexiang Baoxin Pill in non-obstructive coronary artery disease and angina pectoris (2 arms), sponsored by Shanghai Changzheng Hospital. Primary endpoint: Change in Seattle Angina Questionnaire score. Started Mar 2021; status: recruiting.
02
Drugs
Shexiang Baoxin Pill
03
Conditions
non-obstructive coronary artery diseaseangina pectoris
Beyond the preview
Go deeper on ChiCTR2100044737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044737.